Valencia

• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended recruitment
  2024-516473-72-00 5 2025-07-31 Multifocal Motor Neuropathy
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended recruitment
  2024-517356-35-00 4 2025-07-29 Moderately Active Rheumatoid Arthritis
• Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended recruitment
  2024-519575-26-00 4 2025-07-25 Chronic pulmonary aspergillosis (CPA)
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• Leniolisib for immune dysregulation in CVID Ended recruitment
  2024-517725-93-00 4 2025-07-14 Common variable immunodeficiency
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended recruitment
  2023-509067-24-01 4 2025-06-17 - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study) … Ended recruitment
  2024-513511-27-00 4 2025-05-29 HR-negative/HER2-negative resectable stage I TNBC.
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Ended recruitment
  2024-512504-19-00 1 2025-05-28 solid tumors
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef … Ended recruitment
  2024-515907-20-00 9 2025-05-23 Primary biliary cholangitis (PBC)
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• Phase 2 Study of CVN424 Ended recruitment
  2024-516811-25-00 4 2025-05-15 Parkinson Disease

Showing 889–912 of 1,853 trials